Study finds increased cannabis use during pregnancy

Science Spotlight

Cannabis use more than doubled among pregnant women in the United States during the period 2002-2017, according to data collected from 467,100 women aged 12-44 who participated in the National Survey on Drug Use and Health (NSDUH). After adjusting for age, race/ethnicity, and family income, past-month cannabis use, daily/near cannabis use, and number of days of cannabis use all increased among pregnant women. Cannabis use was more common during the first trimester than during the second and third. In addition, cannabis use for medical purposes was relatively rare, but just as frequent among pregnant as non-pregnant women.

Image
Silhouette of a pregnant woman
Image by Pixabay/waldryano

Between 2002-2003 and 2016-2017, past-month cannabis use increased from 3.4% to 7.0% among pregnant women overall and from 5.7% to 12.1% during the first trimester. Daily/near daily cannabis use in the past month increased from 0.9% to 3.4% among pregnant women overall, and from 1.8% to 5.3% during the first trimester; from 0.6% to 2.5% during the second trimester; and from 0.5% to 2.5% during the third trimester.Cannabis use during pregnancy has been associated with effects on fetal growth, including low birth weight and length, and these outcomes may be more likely among women who consume marijuana frequently during pregnancy, especially in the first and second trimesters. This study emphasizes the need to screen and intervene for cannabis use among all pregnant women and underscores the need for additional research to assess fetal outcomes related to prenatal cannabis exposure.

Scientists from the National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) led the research team.

For a copy of the Research Letter, titled "Self-reported medical and nonmedical cannabis use among pregnant women in the United States," and published in JAMA, go to https://jamanetwork.com/journals/jama/article-abstract/2736582. The Research Letter is co-authored by NIDA Director and Deputy Director, Drs. Nora Volkow and Wilson Compton, and SAMHSA’s leader, the Department of Health and Human Services Assistant Secretary for Mental Health and Substance Use Dr. Elinore F. McCance-Katz and SAMHSA Researcher Dr. Beth Han.

For more information about Cannabis, go to Marijuana.

For more information, contact the NIDA press office at media@nida.nih.gov or 301-443-6245. Follow NIDA on Twitter and Facebook.

NIDA Press Office
301-443-6245
media@nida.nih.gov

About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.drugabuse.gov.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®